Preliminary Wound Healing Rates following Application of Various Cellular Based Products 1Donald
Julian
1 Azar ,
BS, Amit
2 Rao ,
MD, and Alisha
and Barbara Zucker School of Medicine at Hofstra/Northwell
Background • Cellular based products are used to provide coverage to open skin wounds and may be composed of biologic, synthetic, or biosynthetic materials. These products are widely used as an adjunct to the management of chronic wounds such as diabetic foot ulcers (DFU), chronic venous ulcers, or pressure ulcers. • The main goal of cellular based products is to replicate the properties of skin, promoting protection and regenerative wound healing. • Different cellular based products have distinct advantages and disadvantages that may make them suitable for specific patients, depending on their wound type, etiology, and wound depth.
2Northwell
Results A total of 70 patients ’ wound healing responses were utilized. Out of these, 46 received Apligraf, 5 Epifix, 1 Puraply, 8 Oasis, and 5 Primatrix. The below graph illustrates the decrease in average wound surface area between the baseline visit and the 6-month follow-up for each patient.
•
Methods • Using the REDCap web application, we entered data from patients seen at the Northwell Health Comprehensive Wound Care Center. • Patients that received cellular based products for their wounds of either DFU, Chronic Venous Ulcer, Pressure Ulcer, or “other” etiology were used for analysis • Patients’ wound measurements (length x width x depth), were recorded starting on the baseline date of Cellular based product application. • Consequently, wound measurements were taken at 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, and 6 months post-first application.
MD
Health Comprehensive Wound Care Center
Conclusions • • • •
All of the cellular based products investigated in this study demonstrate efficacy in wound healing without a significant complication rate. These products were effective in the treatment of wounds with varying etiology. The use of cellular based products is an important factor to assist in wound healing. Cellular based products may vary in their efficacy depending on wound etiology.
Future Direction
Objective • The efficacy of cellular based product depends on wound type, etiology, and product properties. • We investigated the overall healing rates of the products Apligraf, Epifix, Puraply, Grafix, Oasis, and Primatrix over the course of 6 months • Additionally, we investigated the healing rates of each product based on patients’ wound etiology (DFU, Chronic Venous Ulcer, Pressure Ulcer, or Other)
2 Oropallo ,
• •
•
The patient data was then categorized by wound etiology and cellular based product type, as shown below. It should be noted that one recurrent wound outlier was excluded in the calculation of Average Percent Decrease, due to wound complications (one patient receiving Grafix with a pressure ulcer etiology). Additionally, our data set did not include some wound etiologies for specific skin applications. ”Other” etiology includes surgical ulcers, burns, traumatic injuries, etc.
• •
References 1.
Figure 7: Independent CRISPR knockout of CDK4 or CDK6 does not cause dropout in most breast cancer cell lines studied.
More data needs to be acquired to create more statistically reliable results. Specifically, a larger sample size is needed to compare between cellular based product products. Studies should also focus on the comparison of similarly produced cellular based products. Additional studies should also account for the costeffectiveness of these cellular based products.
2. 3.
Figus A, Leon-Villapalos J, Philp B, Dziewulski P. Severe multiple extensive postburn contractures: a simultaneous approach with total scar tissue excision and resurfacing with dermal regeneration template. J Burn Care Res. 2007;28(6):913-917. doi:10.1097/BCR.0b013e318159eb8c Buchanan PJ, Kung TA, Cederna PS. Evidence-Based Medicine: Wound Closure. Plast Reconstr Surg. 2016;138(3 Suppl):257S-70S. doi:10.1097/PRS.0000000000002775 Han G, Ceilley R. Chronic Wound Healing: A Review of Current Management and Treatments. Adv Ther. 2017;34(3):599-610. doi:10.1007/s12325-017-0478-y